COMPASS Pathways Plc · NASDAQ:CMPS
COMPASS Pathways — Investor Presentation (February 2025)
13 slides from COMPASS Pathways's investor presentation, February 2025
Slide 1: Transforming Mental Health Care
Transforming Mental Health Care Investor Presentation February 2025
Slide 2: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. In some cases, you can identify forward-looking statements by terms such as “believe,” “cont
Slide 3: Compass Pathways
Compass Pathways Dedicated to accelerating patient access to evidence-based innovation in mental health. – Lead product candidate: COMP360 psilocybin treatment in treatment resistant depression (TRD) – Phase 2 TRD program published in The New England Journal of Medicine Phase 3 TRD program recruitin
Slide 4: Phase 3 program: Overview of ongoing pivotal trial designs
Phase 3 program: Overview of ongoing pivotal trial designs Week 6 (Part A) Primary endpoint* Randomisation = 2:1 COMP360 Pivotal trial 1 25 mg n = 255 (170:85) Long- Single dose term monotherapy follow-up Top line 6-week data expected (COMP 005) Placebo Q2 2025 Week 6 (Part A) Week 3 Primary endpoin
Slide 5: Phase 3 program long-term follow up component
Phase 3 program long-term follow up component Part A (blinded): Part B (blinded): Part C (open label): Week 6 to week 26 week 26 to week 52 primary endpoint* COMP360 pivotal 25 mg option for trial 1 retreatment COMP360 25mg treatment (005) (same dose (after relapse) n=255 as Part A) Placebo COMP360
Slide 6: Phase 2b trial: Results demonstrate the potential for a rapid, sustained response in TRD
Phase 2b trial: Results demonstrate the potential Published in The NEW ENGLAND JOURNAL of MEDICINE* for a rapid, sustained response in TRD Randomized, controlled, double-blind trial, 3 arms, single dose (either 1mg, 10mg or 25 mg) of COMP360 psilocybin alongside psychological support. Results were m
Slide 7: Phase 2b most frequent TEAEs ordered by the 25mg arm
Phase 2b most frequent TEAEs ordered by the 25mg arm (at least 5% in any treatment group) TEAE incidence is COMP360 COMP360 COMP360 higher in the 25mg Overall 25mg 10mg 1mg group overall MedDRA TEAE preferred term N=79 N=75 N=79 N=233 n (%) Key mood-related Headache 27 (34.2) 16 (21.3) 20 (25.3) 63
Slide 8: Phase 2b trial: COMP360 psilocybin treatment was generally well-tolerated
Phase 2b trial: COMP360 psilocybin treatment was generally well-tolerated Treatment-emergent adverse events There were no concerns with vital signs, ECG or clinical (TEAEs) laboratory data in any of the treatment groups >90% TEAEs involving hallucinations (which only occurred in the of TEAEs were of
Slide 9: Planning for commercial execution through an existing and well-established infrastructure of interventional psychiatry
Planning for commercial execution through an existing and well- established infrastructure of interventional psychiatry treatment centers If approved, COMP360 is expected to be delivered to Current interventional psychiatry treatments are patients through an established infrastructure of delivered f
Slide 10: We are developing a balanced and differentiated pipeline
We are developing a balanced and differentiated pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved Lead COMP360 program in TRD COMP360 for TRD Beyond TRD: We’re assessing the safety and efficacy of COMP360 for PTSD COMP360 psilocybin therapy for PTSD and anorexia COMP360 for anorexia ne
Slide 11: Phase 2 PTSD study safety profile (primary endpoint)
Phase 2 PTSD study safety profile (primary endpoint) Summary of most frequent TEAES (≥10% prevalence) COMP360 was well tolerated with no treatment emergent serious adverse events reported No participants re-started SSRI’s or antidepressants after COMP360 administration in study There were 2 events o
Slide 12: Post-traumatic stress disorder (PTSD) positive phase 2 study
Post-traumatic stress disorder (PTSD) positive phase 2 study Summary of change from baseline in CAPS-5 score ➢ N=22, multi-center open-label, single administration of 25mg COMP360 with psychological support ➢ Early onset and sustained change from baseline in CAPS- 5 observed at week 4 and week 12 ➢
Slide 13: We're a biotechnology company…
We're a biotechnology company… …dedicated to accelerating patient access to evidence-based innovation in mental health. Stephen Schultz SVP, Investor Relations stephen.schultz@compasspathways.com +1 401-290-7324 14 | © Compass Pathways
COMPASS Pathways — Investor Presentation (February 2025) on 6ix